Component

Red yeast rice preparation in the Becker 2009 trial

Context-specific entity; species, compartment and exposure are stated on each claim.

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. In 62 statin-intolerant participants, the studied red yeast rice regimen reduced LDL by 43 mg/dL at 12 weeks and 35 mg/dL at 24 weeks, versus 11 and 15 mg/dL with placebo.

    Red yeast rice preparation in the Becker 2009 trial → LDL cholesterol concentration source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    1,800 mg twice daily for 24 weeks; both groups also entered a lifestyle program.
    limitations
    Small selected population; formulation-specific lipid result, not proof of cardiovascular-event reduction.
    nutrient_topic
    Red yeast rice collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · Red yeast rice
    plain_language
    This particular preparation lowered LDL in a randomized trial.
    primary_references
    [19528562] Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. · 2009 · https://pubmed.ncbi.nlm.nih.gov/19528562/ · DOI 10.7326/0003-4819-150-12-200906160-00006

    Red yeast rice: constituents, mevalonate, CoQ and product-specific interactions (2026-09-20) · lines 340–346

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · 1,800 mg twice daily for 24 weeks; both groups also entered a lifestyle program. · source_derived_draft · unverified_draft

    ## red-yeast-rice-becker-ldl This particular preparation lowered LDL in a randomized trial. In 62 statin-intolerant participants, the studied red yeast rice regimen reduced LDL by 43 mg/dL at 12 weeks and 35 mg/dL at 24 weeks, versus 11 and 15 mg/dL with placebo. Model: 1,800 mg twice daily for 24 weeks; both groups also entered a lifestyle program. Limitations: Small selected population; formulation-specific lipid result, not proof of cardiovascular-event reduction. Evidence access: Primary abstract [19528562] Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. · 2009 · https://pubmed.ncbi.nlm.nih.gov/19528562/ · DOI 10.7326/0003-4819-150-12-200906160-00006
    Complete structured claim and evidence

  2. Pain, CPK and liver-enzyme results did not differ significantly between groups in the 24-week trial.

    Red yeast rice preparation in the Becker 2009 trial → Pain and creatine-kinase endpoints in the Becker red yeast rice trial source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    62 previously statin-intolerant participants.
    limitations
    Insufficient to exclude rare muscle or liver injury, or establish that all red yeast rice is safer than statins.
    nutrient_topic
    Red yeast rice collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · Red yeast rice
    plain_language
    The trial retained tolerability outcomes as well as LDL changes.
    primary_references
    [19528562] Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. · 2009 · https://pubmed.ncbi.nlm.nih.gov/19528562/ · DOI 10.7326/0003-4819-150-12-200906160-00006

    Red yeast rice: constituents, mevalonate, CoQ and product-specific interactions (2026-09-20) · lines 348–354

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · 62 previously statin-intolerant participants. · source_derived_draft · unverified_draft

    ## red-yeast-rice-becker-tolerability The trial retained tolerability outcomes as well as LDL changes. Pain, CPK and liver-enzyme results did not differ significantly between groups in the 24-week trial. Model: 62 previously statin-intolerant participants. Limitations: Insufficient to exclude rare muscle or liver injury, or establish that all red yeast rice is safer than statins. Evidence access: Primary abstract [19528562] Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. · 2009 · https://pubmed.ncbi.nlm.nih.gov/19528562/ · DOI 10.7326/0003-4819-150-12-200906160-00006
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards